Dries Deleersnijder

Dries Deleersnijder

Auto-generated profile, based on publicly available information

Dries Deleersnijder

Division of Nephrology, University Hospitals Leuven, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2022 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
WLWim Laurens
Wim Laurens
DDDries Deleersnijder
Dries Deleersnijder
ADAmélie Dendooven
Amélie Dendooven
ELEvelyne Lerut
Evelyne Lerut
AVAn S De Vriese
An S De Vriese
BSBen Sprangers
Ben Sprangers
Background: The Flemish Collaborative Glomerulonephritis Group (FCGG) registry is the first population-based native kidney biopsy registry in Flanders, Belgium. In this first analysis, we report on patient demographics, frequency distribution and incidence rate of biopsied kidney disease in adults in Flanders. Methods: From January 2017 to December 2019, a total of 2054 adult first native kidney biopsies were included. A ‘double diagnostic coding’ strategy was used, in which every biopsy sample received a histopathological and final clinical diagnosis. Frequency distribution and incidence rate of both diagnoses were reported and compared with other European registries. Results: The median age at biopsy was 61.1 years (interquartile range, 46.1–71.7); male patients were more prevalent (62.1%) and biopsy incidence rate was 129.3 per million persons per year. Immunoglobulin A nephropathy was the most frequently diagnosed kidney disease (355 biopsies, 17.3% of total) with a similar frequency as in previously published European registries. The frequency of tubulointerstitial nephritis (220 biopsies, 10.7%) and diabetic kidney disease (154 biopsies, 7.5%) was remarkably higher, which may be attributed to changes in disease incidence as well as biopsy practices. Discordances between histopathological and final clinical diagnoses were noted and indicate areas for improvement in diagnostic coding systems. Conclusions: The FCGG registry, with its ‘double diagnostic coding’ strategy, provides useful population-based epidemiological data on a large Western European population and allows subgroup selection for future research.

13 September 2025 in Advances in Kidney Disease and Health
Verified
Journal Article
Closed access
NWNina Teresa Weber
Nina Teresa Weber
DDDries Deleersnijder
Dries Deleersnijder
AKAbhijat Kitchlu
Abhijat Kitchlu
BSBen Sprangers
Ben Sprangers

14 July 2021 in Glomerular Diseases
Verified
Journal Article
Open access
PDF file
DDDries Deleersnijder
Dries Deleersnijder
ACAmaryllis H Van Craenenbroeck
Amaryllis H Van Craenenbroeck
BSBen Sprangers
Ben Sprangers
Background: Focal segmental glomerulosclerosis is a histopathological pattern of renal injury and comprises a heterogeneous group of clinical conditions with different pathophysiology, clinical course, prognosis, and treatment. Nevertheless, subtype differentiation in clinical practice often remains challenging, and we currently lack reliable diagnostic, prognostic, and therapeutic biomarkers. The advent of new transcriptomics techniques in kidney research poses great potential in the identification of gene expression biomarkers that can be applied in clinical practice. Summary: Transcriptomics techniques have been completely revolutionized in the last 2 decades, with the evolution from low-throughput reverse-transcription polymerase chain reaction and in situ hybridization techniques to microarrays and next-generation sequencing techniques, including RNA-sequencing and single-cell transcriptomics. The integration of human gene expression profiles with functional in vitro and in vivo experiments provides a deeper mechanistic insight into the candidate genes, which enable the development of novel-targeted therapies. The correlation of gene expression profiles with clinical outcomes of large patient cohorts allows for the development of clinically applicable biomarkers that can aid in diagnosis and predict prognosis and therapy response. Finally, the integration of transcriptomics with other “omics” modalities creates a holistic view on disease pathophysiology. Key Messages: New transcriptomics techniques allow high-throughput gene expression profiling of patients with focal segmental glomerulosclerosis (FSGS). The integration with clinical outcomes and fundamental mechanistic studies enables the discovery of new clinically useful biomarkers that will finally improve the clinical outcome of patients with FSGS.

26 January 2021 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
DDD. Deleersnijder
D. Deleersnijder
PHP. De Haes
P. De Haes
LPL. Peperstraete
L. Peperstraete
JBJ. Buelens
J. Buelens
ABA. Betrains
A. Betrains
DBD. Blockmans
D. Blockmans

13 October 2022 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
DDDries Deleersnijder
Dries Deleersnijder
NKNoël Knops
Noël Knops
DTDominique Trouet
Dominique Trouet
KHKoen Van Hoeck
Koen Van Hoeck
SKSevasti Karamaria
Sevasti Karamaria
OGon behalf of the FCGG collaborative group
on behalf of the FCGG collaborative group

21 February 2025 in Clinical Kidney Journal
Verified
Journal Article
Open access
DDDries Deleersnijder
Dries Deleersnijder
ECEvert Cleenders
Evert Cleenders
MCMaarten Coemans
Maarten Coemans
ADAmélie Dendooven
Amélie Dendooven
PKPriyanka Koshy
Priyanka Koshy
ACAmaryllis H Van Craenenbroeck
Amaryllis H Van Craenenbroeck
Background: Studies that compare kidney outcomes across patients with different forms of focal segmental glomerulosclerosis (FSGS) are lacking. Methods: This retrospective study compared annual estimated glomerular filtration rate (eGFR) slope and kidney failure rate (eGFR <15 mL/min/1.73 m2 or initiation of kidney replacement therapy) across patients with biopsy-proven primary, maladaptive, genetic and undetermined FSGS. Patients were included from two Belgian tertiary referral hospitals, from 2010 until 2022. Associations between covariates and kidney failure were estimated using Cox and Fine and Gray models. eGFR slopes were estimated using linear mixed-effects models. Results: Eighty-two patients were subdivided into primary (28.1%), maladaptive (40.2%), genetic (14.6%) and undetermined FSGS (17.1%) groups. Kidney failure occurred in 22 patients (26.8%). Primary FSGS patients exhibited higher baseline eGFR and less chronic changes on biopsy. The annual eGFR slope was –2.5 mL/min in primary, –2.5 mL/min in maladaptive, –4.6 mL/min in genetic and –4.4 mL/min in undetermined FSGS. Female sex was associated with a lower kidney failure rate and higher eGFR slope. Higher proteinuria at biopsy was associated with a higher kidney failure rate, lower eGFR slope and a higher mortality rate. Global sclerosis on kidney biopsy was associated with lower baseline eGFR, while a higher percentage of segmental sclerosis rather associated with more rapid eGFR decline [–1.5 mL/min/year per 10% increase, 95% confidence interval (–2.2, –0.7)]. Conclusions: Patients with primary FSGS were biopsied earlier in their disease course and exhibited surprisingly good kidney outcome. Overall, sex, baseline eGFR, proteinuria and the degree of focal and global glomerulosclerosis play a more important role in estimating the prognosis of patients with FSGS than merely the FSGS etiology.